Mineralys Therapeutics to Participate in the Jefferies Global Healthcare Conference

About this update from Mineralys Therapeutics, Inc.

RADNOR, Pa., May 27, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced that management will be participating in the Jefferies 2026 Global Healthcare Conference being held in New York on June 2-4, 2026. A live webcast of this presentation can also be accessed on the “ News & Events ” page in the Investor Relations section of the Mineralys Therapeutics website. About Mineralys Therapeutics Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit  https://mineralystx.com . Follow Mineralys on  LinkedIn ,  Twitter  and  Bluesky . Contact: Investor Relations [email protected] Media Relations Melyssa Weible Elixir Health Public Relations Email:  [email protected]

View stock analysis, news, and events for Mineralys Therapeutics, Inc.